vs
Akebia Therapeutics, Inc.（AKBA）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
Akebia Therapeutics, Inc.的季度营收约是REGIS CORP的1.0倍（$57.6M vs $57.1M），Akebia Therapeutics, Inc.同比增速更快（23.9% vs 22.3%），Akebia Therapeutics, Inc.自由现金流更多（$31.1M vs $891.0K），过去两年Akebia Therapeutics, Inc.的营收复合增速更高（32.9% vs 7.8%）
Akebia Therapeutics是一家专注于肾病领域的生物制药企业，核心业务覆盖药物研发、临床试验及商业化推广全流程，主要开发针对慢性肾病相关贫血等适应症的创新疗法，面向全球市场，致力于满足肾病治疗领域未被满足的临床需求。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
AKBA vs RGS — 直观对比
营收规模更大
AKBA
是对方的1.0倍
$57.1M
营收增速更快
AKBA
高出1.7%
22.3%
自由现金流更多
AKBA
多$30.2M
$891.0K
两年增速更快
AKBA
近两年复合增速
7.8%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $57.6M | $57.1M |
| 净利润 | — | $456.0K |
| 毛利率 | 78.2% | — |
| 营业利润率 | -14.8% | 10.8% |
| 净利率 | — | 0.8% |
| 营收同比 | 23.9% | 22.3% |
| 净利润同比 | — | -94.0% |
| 每股收益（稀释后） | $-0.05 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AKBARGS
| Q4 25 | $57.6M | $57.1M | ||
| Q3 25 | $58.8M | $59.0M | ||
| Q2 25 | $62.5M | $60.4M | ||
| Q1 25 | $57.3M | $57.0M | ||
| Q4 24 | $46.5M | $46.7M | ||
| Q3 24 | $37.4M | $46.1M | ||
| Q2 24 | $43.6M | $49.4M | ||
| Q1 24 | $32.6M | $49.2M |
净利润AKBARGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $540.0K | $1.4M | ||
| Q2 25 | $247.0K | $116.5M | ||
| Q1 25 | $6.1M | $250.0K | ||
| Q4 24 | — | $7.6M | ||
| Q3 24 | $-20.0M | $-853.0K | ||
| Q2 24 | $-8.6M | $91.2M | ||
| Q1 24 | $-18.0M | $-2.3M |
毛利率AKBARGS
| Q4 25 | 78.2% | — | ||
| Q3 25 | 84.0% | — | ||
| Q2 25 | 84.1% | — | ||
| Q1 25 | 86.7% | — | ||
| Q4 24 | 56.2% | — | ||
| Q3 24 | 62.2% | — | ||
| Q2 24 | 60.9% | — | ||
| Q1 24 | 64.4% | — |
营业利润率AKBARGS
| Q4 25 | -14.8% | 10.8% | ||
| Q3 25 | 7.6% | 10.0% | ||
| Q2 25 | 22.6% | 12.1% | ||
| Q1 25 | 23.6% | 8.8% | ||
| Q4 24 | -30.8% | 11.8% | ||
| Q3 24 | -33.4% | 4.6% | ||
| Q2 24 | -20.0% | — | ||
| Q1 24 | -45.8% | 8.3% |
净利率AKBARGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | 0.9% | 2.3% | ||
| Q2 25 | 0.4% | 192.9% | ||
| Q1 25 | 10.7% | 0.4% | ||
| Q4 24 | — | 16.4% | ||
| Q3 24 | -53.5% | -1.9% | ||
| Q2 24 | -19.7% | 184.7% | ||
| Q1 24 | -55.2% | -4.7% |
每股收益（稀释后）AKBARGS
| Q4 25 | $-0.05 | $0.16 | ||
| Q3 25 | $0.00 | $0.49 | ||
| Q2 25 | $0.00 | $43.67 | ||
| Q1 25 | $0.03 | $0.08 | ||
| Q4 24 | $-0.10 | $2.71 | ||
| Q3 24 | $-0.10 | $-0.36 | ||
| Q2 24 | $-0.04 | $38.40 | ||
| Q1 24 | $-0.09 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $184.8M | $18.4M |
| 总债务越低越好 | $48.3M | $113.3M |
| 股东权益账面价值 | $32.6M | $188.7M |
| 总资产 | $376.6M | $588.3M |
| 负债/权益比越低杠杆越低 | 1.48× | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资AKBARGS
| Q4 25 | $184.8M | $18.4M | ||
| Q3 25 | $166.4M | $16.6M | ||
| Q2 25 | $137.3M | $17.0M | ||
| Q1 25 | $113.4M | $13.3M | ||
| Q4 24 | $51.9M | $10.2M | ||
| Q3 24 | $34.0M | $6.3M | ||
| Q2 24 | $39.5M | $10.1M | ||
| Q1 24 | $42.0M | $5.9M |
总债务AKBARGS
| Q4 25 | $48.3M | $113.3M | ||
| Q3 25 | $47.6M | $111.3M | ||
| Q2 25 | $47.1M | $110.8M | ||
| Q1 25 | $46.5M | $112.0M | ||
| Q4 24 | $38.7M | $111.5M | ||
| Q3 24 | $38.4M | $95.2M | ||
| Q2 24 | $38.0M | $99.5M | ||
| Q1 24 | $30.1M | $179.7M |
股东权益AKBARGS
| Q4 25 | $32.6M | $188.7M | ||
| Q3 25 | $41.6M | $187.6M | ||
| Q2 25 | $29.2M | $185.6M | ||
| Q1 25 | $24.6M | $68.6M | ||
| Q4 24 | $-49.2M | $66.7M | ||
| Q3 24 | $-50.4M | $56.4M | ||
| Q2 24 | $-33.8M | $56.8M | ||
| Q1 24 | $-27.3M | $-35.8M |
总资产AKBARGS
| Q4 25 | $376.6M | $588.3M | ||
| Q3 25 | $364.2M | $592.1M | ||
| Q2 25 | $345.6M | $599.0M | ||
| Q1 25 | $310.2M | $511.2M | ||
| Q4 24 | $220.7M | $530.1M | ||
| Q3 24 | $207.1M | $508.9M | ||
| Q2 24 | $220.2M | $530.5M | ||
| Q1 24 | $225.5M | $543.7M |
负债/权益比AKBARGS
| Q4 25 | 1.48× | 0.60× | ||
| Q3 25 | 1.15× | 0.59× | ||
| Q2 25 | 1.61× | 0.60× | ||
| Q1 25 | 1.89× | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $31.1M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | $31.1M | $891.0K |
| 自由现金流率自由现金流/营收 | 53.9% | 1.6% |
| 资本支出强度资本支出/营收 | 0.1% | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | $67.7M | $14.9M |
8季度趋势，按日历期对齐
经营现金流AKBARGS
| Q4 25 | $31.1M | $1.7M | ||
| Q3 25 | $28.1M | $2.3M | ||
| Q2 25 | $22.3M | $6.8M | ||
| Q1 25 | $-13.6M | $6.2M | ||
| Q4 24 | $-4.5M | $2.1M | ||
| Q3 24 | $-6.7M | $-1.3M | ||
| Q2 24 | $-10.1M | $5.1M | ||
| Q1 24 | $-19.4M | $-277.0K |
自由现金流AKBARGS
| Q4 25 | $31.1M | $891.0K | ||
| Q3 25 | $28.0M | $1.9M | ||
| Q2 25 | $22.2M | $6.2M | ||
| Q1 25 | $-13.6M | $5.9M | ||
| Q4 24 | $-4.5M | $1.7M | ||
| Q3 24 | $-6.7M | $-1.4M | ||
| Q2 24 | $-10.1M | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率AKBARGS
| Q4 25 | 53.9% | 1.6% | ||
| Q3 25 | 47.7% | 3.2% | ||
| Q2 25 | 35.6% | 10.3% | ||
| Q1 25 | -23.7% | 10.3% | ||
| Q4 24 | -9.6% | 3.6% | ||
| Q3 24 | -17.9% | -3.0% | ||
| Q2 24 | -23.1% | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度AKBARGS
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 0.1% | 0.7% | ||
| Q2 25 | 0.2% | 0.9% | ||
| Q1 25 | 0.0% | 0.6% | ||
| Q4 24 | 0.0% | 0.9% | ||
| Q3 24 | 0.0% | 0.0% | ||
| Q2 24 | 0.1% | 0.0% | ||
| Q1 24 | 0.0% | 0.1% |
现金转化率AKBARGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | 52.05× | 1.68× | ||
| Q2 25 | 90.47× | 0.06× | ||
| Q1 25 | -2.22× | 24.80× | ||
| Q4 24 | — | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKBA
| Auryxia | $48.1M | 84% |
| Vafseo | $6.2M | 11% |
| License Collaboration And Other Revenue | $3.3M | 6% |
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
